{
  "date": "2021-01-01",
  "title": "FDA Regulatory Capture in Pharmaceutical Sector: Keytruda Case Study",
  "summary": "Keytruda (pembrolizumab) generates over 4 billion in 2020 and 7 billion in 2021, exemplifying regulatory capture where FDA approval processes serve industry interests over public health. The monoclonal antibody market demonstrates cascading effects as financial processes impact health systems and compound patient care costs, with shareholders demanding high returns that cascade to higher premiums and limited coverage.",
  "importance": 8,
  "status": "confirmed",
  "actors": [
    "FDA",
    "Merck",
    "Keytruda",
    "Pharmaceutical Industry"
  ],
  "sources": [
    "https://www.sciencedirect.com/science/article/pii/S027795362400042X"
  ],
  "tags": [
    "regulatory capture",
    "pharmaceutical",
    "FDA",
    "cascading effects",
    "healthcare costs"
  ],
  "id": "2021-01-01--fda-regulatory-capture-in-pharmaceutical-sector:-keytruda-case-study-1757454506",
  "priority_id": "RP-20250909-capture-cascade-part-6-the-cascade"
}